18559859. DOSING REGIMENS simplified abstract (Novartis AG)

From WikiPatents
Revision as of 05:38, 26 July 2024 by Wikipatents (talk | contribs) (Creating a new page)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

DOSING REGIMENS

Organization Name

Novartis AG

Inventor(s)

Stephanie Kay Dodd of Ayer MA (US)

Florence Hourcade-potelleret of Landser (FR)

Felix Huth of Muttenz (CH)

Michelle Quinlan of Morris Plains NJ (US)

Julia Zack of Jersey City NJ (US)

DOSING REGIMENS - A simplified explanation of the abstract

This abstract first appeared for US patent application 18559859 titled 'DOSING REGIMENS

The present disclosure discusses dosing regimens and combinations containing N-[4-(Chlorodifluoromethoxy)phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-(1H-pyrazol-5-yl)pyridine-3-carboxamide or a pharmaceutically acceptable salt thereof for treating BCR-ABL mediated diseases or disorders.

  • This patent application focuses on a specific compound and its salt for the treatment of diseases mediated by BCR-ABL protein.
  • The dosing regimens and combinations provided in this patent aim to target and inhibit the activity of BCR-ABL protein effectively.
  • The innovation lies in the use of N-[4-(Chlorodifluoromethoxy)phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-(1H-pyrazol-5-yl)pyridine-3-carboxamide or its salt as a potential therapeutic agent for BCR-ABL mediated diseases.
  • The patent application suggests novel treatment approaches for diseases associated with BCR-ABL protein, offering potential benefits to patients.
  • This technology has the potential to revolutionize the treatment landscape for BCR-ABL mediated diseases, providing new hope for patients with such conditions.

Potential Applications: The technology can be applied in the development of targeted therapies for various BCR-ABL mediated diseases such as certain types of leukemia. It can be utilized in clinical settings for personalized medicine approaches tailored to individual patients with BCR-ABL positive conditions.

Problems Solved: This technology addresses the challenge of effectively targeting and inhibiting the activity of BCR-ABL protein in diseases where it plays a crucial role. It offers a new treatment option for patients with BCR-ABL mediated diseases who may have limited therapeutic choices.

Benefits: The use of N-[4-(Chlorodifluoromethoxy)phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-(1H-pyrazol-5-yl)pyridine-3-carboxamide or its salt can lead to improved outcomes and quality of life for patients with BCR-ABL mediated diseases. It has the potential to enhance treatment efficacy and reduce side effects compared to existing therapies for these conditions.

Commercial Applications: The technology could be of interest to pharmaceutical companies involved in the development of targeted therapies for cancer and other BCR-ABL mediated diseases. It may have significant market implications in the field of precision medicine and personalized treatment approaches for patients with specific genetic mutations.

Questions about BCR-ABL mediated diseases: 1. How does the compound N-[4-(Chlorodifluoromethoxy)phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-(1H-pyrazol-5-yl)pyridine-3-carboxamide target BCR-ABL protein in diseases? 2. What potential challenges or limitations could arise in the clinical application of this technology?


Original Abstract Submitted

The present disclosure relates to dosing regimens and combinations comprising N-[4-(Chlorodifluoromethoxy)phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-(1H-pyrazol-5-yl)pyridine-3-carboxamide or a pharmaceutically acceptable salt thereof, and their use for the treatment of breakpoint cluster region-abelson protein (BCR-ABL) mediated diseases or disorders.

Retrieved from "http://wikipatents.org/index.php?title=18559859._DOSING_REGIMENS_simplified_abstract_(Novartis_AG)&oldid=206695"